# A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

> **NCT05924256** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 88 (estimated)

## Conditions studied

- Advanced Salivary Gland Carcinoma

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** SHR 3680 + leuprolide
- **DRUG:** SHR-A1921
- **DRUG:** SHR-A1811

## Key facts

- **NCT ID:** NCT05924256
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-26
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05924256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05924256, "A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05924256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*